RECEIVED
CENTRAL FAX GENTER

427.098

JUL 2 2 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lydic Poitout, et al.

Serial No.: 10/550,122

Filed: September 19, 2005

For: IMIDAZOPYRIDINE ... AGONISTS:

Group: 1625

Examiner: Rahmani, Niloofar

Hedman and Costigan

1185 Avenue of the Americas

New York, NY 10036

July 22, 2008

RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Responsive to the Office action of February 22, 2008, Applicants request reconsideration of the application in view of the declaration of Dr. Thurieau filed berewith.

The claims in the application are claims 1 to 17 and 23 to 27, all other claims being cancelled. Claims 1 to 17 stand allowed.

Claims 23 to 27 stand rejected under 35 USC 112, first paragraph since the Examiner deems the specification does not enable the instant compounds to alter the gene expression and therefore to treat any and all known or unknown diseases.